InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces a pivotal milestone in the development of ICP-488, its novel TYK2 JH2 allosteric inhibitor, for the treatment of psoriasis. The company has successfully completed patient enrollment for the phase II clinical trial, marking a significant step forward in addressing the unmet medical needs of psoriasis patients.

The multicenter, randomized, double-blind, placebo-controlled phase II clinical trial aims to assess the efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of ICP-488 in Chinese adult patients with moderate to severe plaque psoriasis. A total of 129 patients have been enrolled in this study, representing a diverse cohort essential for robust evaluation.

Patients have been randomly assigned to one of three treatment groups in a 1:1:1 ratio, receiving either a 6mg once-daily dose, a 9mg once-daily dose, or a placebo, over a 12-week treatment period. This rigorous design ensures comprehensive evaluation of ICP-488's therapeutic potential.

ICP-488, an oral, potent, and selective TYK2 allosteric inhibitor, acts by binding to the JH2 domain, thereby blocking the signal transduction of key inflammatory cytokines such as IL-23, IL-12, and type 1 IFN. This mechanism offers promise in inhibiting the pathological processes underlying autoimmune and inflammatory diseases, including psoriasis. Notably, ICP-488 has demonstrated encouraging efficacy and safety profiles in phase I studies involving psoriasis patients.

Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, emphasized the pressing need for innovative psoriasis treatments, stating, "Psoriasis necessitates long-term management, yet there remains a significant gap in effective, especially oral, medications. We are delighted to achieve this pivotal milestone in our clinical journey with ICP-488. Our commitment to advancing this promising therapy underscores our dedication to meeting the evolving needs of psoriasis patients."

Psoriasis affects approximately seven million individuals in China, with the prevalence steadily increasing. Existing treatment modalities often fall short in addressing the complexities of this condition, leaving many patients undertreated or untreated. The demand for novel, oral medications is particularly acute, underscoring the urgency of advancing therapies like ICP-488 to address this unmet medical need effectively.

InnoCare remains steadfast in its mission to bring innovative therapies to patients, and the progress achieved in the phase II clinical trial of ICP-488 represents a significant step forward in realizing this vision.